Hematological, Biochemical, and Serological Findings in Healthy Canine Blood Donors after the Administration of CaniLeish® Vaccine by Starita, Chiara et al.
Research Article
Hematological, Biochemical, and Serological
Findings in Healthy Canine Blood Donors after
the Administration of CaniLeish„ Vaccine
Chiara Starita, Alessandra Gavazza, and George Lubas
Department of Veterinary Sciences, University of Pisa, Via Livornese Lato Monte, San Piero a Grado, 56122 Pisa, Italy
Correspondence should be addressed to Alessandra Gavazza; agavazza@vet.unipi.it
Received 29 October 2015; Revised 13 April 2016; Accepted 27 April 2016
Academic Editor: Timm C. Harder
Copyright © 2016 Chiara Starita et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The aim of the study was to evaluate hematological, biochemical, and serological findings in healthy canine blood donors after
the administration of CaniLeish vaccine. Twenty-seven client-owned dogs were included in the study and arranged into 3 groups
according to the vaccination stage. Complete blood count (CBC) with blood smear examination, serum biochemical profile (SBP),
serum protein electrophoresis (SPE), and serological tests for L. infantum were performed at different times. Additionally, in a
subgroup of dogs IgA, IgM, and IgG were quantified. No statistical significance for CBC and SBP was found. In 10.7% of cases
slight hyperproteinemia occurred. In SPE absolute values 𝛽-1-globulins (Group 2 and Group 2-3) and 𝛽-2-globulins (Group 3)
were found modified (𝑃 < 0.05). IgG values were statistically different (𝑃 < 0.05) 6–8 months after the third immunisation (Group
2) and IgM and IgG values were statistically different after 2 months (Group 3). IFAT positive samples were 20.8% (Group 1), 15.0%
(Group 2), and 52.8% (Group 3). Speed Leish K tests were always negative. The modifications found were probably attributed to
the development of immune or inflammatory response due to the vaccine. Administration of CaniLeish vaccine in canine blood
donors could be a safe practice and did not affect their health status.
1. Introduction
Canine leishmaniosis is caused by an intracellular protozoan
called Leishmania infantum transmitted by sand flies of the
genusPhlebotomus.Theprogression from infection to clinical
disease occurs if the canine cell-mediated immune response
is inadequate and the parasite increases in number within
macrophages in many organs and tissues [1].
The prevention of canine leishmaniosis requires a com-
bined approach including measures focused both on dogs
and on environment [2–4]. A canine vaccine that modulates
cell-mediated immune response against the protozoan has
been available in Italy since 2012 (CaniLeish, Virbac, France).
It reduces the risk of developing, after the contact with the
parasite, from an active infection to a symptomatic disease
[5–7]. In addition, it may help those dogs that get infected
despite vaccination, as suggested by a recent study using
xenodiagnosis, since disease severity appears to be generally
associated with high parasite loads in the skin and their
infectivity [8].
Hence, the control of leishmaniosis is particularly impor-
tant in canine blood donors because the risk of transmis-
sion of infectious agents through transfused blood prod-
ucts from blood donors, that are carriers of infection, is
demonstrated [9–11]. Overall, protozoan diseases have long
incubation periods, subclinical persistence in infected ani-
mals, and likelihood of remaining viable in bloodstocks [10,
11].
The recently revised Italian guidelines about veterinary
transfusion medicine established by the Ministry of Health
[12] stated that blood donor dogs should be healthy ani-
mals and should undergo complete clinical examination and
laboratory tests including hematobiochemical profile and
serological assay, using IFAT, or PCR for Leishmania infan-
tum, Ehrlichia canis, Anaplasma phagocytophilum, Rickettsia
rickettsii, and Babesia canis [13].
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In order to increase the prevention of leishmaniosis in
blood donors, the vaccine against leishmaniosis could be
used. To the author’s knowledge no data has been published
about the evaluation of hematological and biochemical find-
ings after administration of CaniLeish. Therefore, the aim of
this study was to evaluate hematological, biochemical, and
serological findings in a group of healthy dogs participating
in a voluntary blood donor program at the Transfusion
VeterinaryCentre,University of Pisa, receiving a full coverage
of immunisation with CaniLeish.
2. Materials and Methods
2.1. SelectionCriteria. Thestudy took place betweenFebruary
2013 and July 2014 in the area of northern Tuscany, Italy.
Twenty-seven client-owned dogs participating in a voluntary
blood donor program at the University of Pisa were included
(written consent was previously collected from all the own-
ers). The following selection criteria were used to include
dogs as blood donors: Dog Erythrocyte Antigen (DEA) 1
negative, absence of any clinical signs or symptoms of disease,
values of complete blood count (CBC) (ProCyte Dx, Idexx,
Italy) and blood smear examination, serum biochemical pro-
file (SBP) (total protein, albumin, urea, alkaline phosphatase,
and alanine aminotransferase) (Liasys, Assel, Italy), and
serum protein electrophoresis (SPE) in agarose gel (Pretty,
Interlab, Italy) within the reference ranges of the Veterinary
Clinical Pathology University Laboratory: negative serology
for Leishmania infantum using immunofluorescence anti-
body test (IFAT) [14] and Speed Leish K test, negative
serology for Ehrlichia canis and Anaplasma phagocytophilum
using IFAT [15]. Any serological positivity titre starting from
1 : 40 was an exclusion cause from the blood donors program.
Moreover, all dogs received a regular protection against
ectoparasites, both repellent and/or antifeeding drugs applied
locally.
2.2. Vaccine Administration. Lyophilized CaniLeish vaccine
(Virbac, France) stored at +4/+10∘C was reconstituted with
its solvent (approximately 1mL) and administered subcuta-
neously in the withers region followed by a gentle massage
of the site. Dogs were monitored for 30 minutes in order
to observe the onset of possible anaphylactic reactions. The
owners were advised to report to the authors any suspected
reaction or adverse effect that might occur and in that
case they would have undergone a control. The vaccine
was administered according to the protocol indicated in the
manufacturer’s instructions: first cycle of 3 inoculations, each
of them every 3 weeks, and annual boosters for further
administration.
2.3. Study Design. Twenty-seven canine blood donors (17
females, 10 males; 14 Boxers, 8 mixed breeds, 3 Golden
Retrievers, 1Weimaraner, 1 Border Collie; 2–7 years old) were
included in the study. Dogs were divided into three groups
according to the vaccination stage. Group 1 included 6 dogs
that underwent first and second annual boosters because they
had already completed the first cycle of immunisation by
their referring veterinarian. Group 2 included 12 dogs, which
underwent the first cycle of immunisation and first annual
booster. Group 3 included 9 dogs, which underwent only the
first cycle of immunisation. The times (𝑇) in days of controls
were 𝑇0 (first immunisation), 𝑇21 (second immunisation),
𝑇42 (third immunisation), 𝑇100 (two months after the third
immunisation), 𝑇250 (6–8 months after the third immunisa-
tion), 𝑇405 (first annual booster), and 𝑇770 (second annual
booster). About 10mL of blood was withdrawn from the
jugular or cephalic vein for laboratory analysis. For Group
1 only serological assays (IFAT L. infantum and Speed Leish
K) were performed at 𝑇0, 𝑇250, 𝑇405, and 𝑇770. For Group
2, CBC with blood smear examination, serum biochemical
profile (total protein, albumin, urea, alkaline phosphatase,
and alanine aminotransferase), serum electrophoresis, IFAT
for L. infantum, and Speed Leish K were provided at 𝑇0,
𝑇21, 𝑇42, 𝑇250, and 𝑇405. In Group 3, the same laboratory
tests of Group 2 were performed at 𝑇0, 𝑇21, 𝑇42, and 𝑇100.
Group 2 and Group 3 were evaluated together as Group 2-3
whenever possible, for comparison purposes. Moreover, for a
subgroup of dogs (10/12 of Group 2 and 7/9 of Group 3) IgA
(immunoglobulin), IgM, and IgG fractions were quantified,
respectively, at 𝑇0–𝑇100 and 𝑇0–𝑇250 using the method
described by Tvarijonaviciute [16]. Briefly, commercial kits
(Olympus EuropeGmbH)were run on an automatic analyzer
(Olympus AU600, Olympus Europe GmbH, Hamburg, Ger-
many) following the manufacturer’s instruction.
2.4. Statistics. Data distribution was assessed through the
D’Agostino-Pearson test. The Kruskal-Wallis test was per-
formed for CBC, SBP, and SPE data, while for immunoglobu-
lin the Wilcoxon test was provided. For all tests, significance
was set as 𝑃 < 0.05. Statistical analysis was performed using
commercial software (MedCalc Software v.14.8.1.0, Mariak-
erke, Belgium).
3. Results
3.1. Hematobiochemical Analysis. No statistical significance
for data from CBC and SBP was found (data not shown).
However, slight hyperproteinemia up to 8.4 g/dL (reference
range 5.8–7.8 g/dL) occurred in 10.7% of cases. Results from
SPE are shown in Table 1 as absolute values using median
and 95% confidence interval. Our data show a statistical
significance (𝑃 < 0.05) of𝛽-1-globulins inGroup 2 andGroup
2-3 and of 𝛽-2-globulins in Group 3. Tables 2 and 3 report the
results of the quantification of IgA, IgM, and IgG in Groups 2
and 3, respectively. The IgG values were statistically different
(𝑃 < 0.05) at 𝑇250 for Group 2, while IgM and IgG values
were statistically different (𝑃 < 0.05) at 𝑇100 in Group 3.
3.2. Serological Tests. The results of IFAT are reported in
Table 4 (and Figures 1, 2, and 3). In Group 1, 20.8% of
canine samples were positive at low titres (up to 1 : 80), in
Group 2, 15.0% of samples were positive at rather low titres
(mostly up to 1 : 80, one dog up to 1 : 320), and, in Group 3,
52.8% of samples were positive at rather low and high titres
(mostly 1 : 80 and 1 : 160, one dog up to 1 : 320). In detail, in
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Table 1: Major serum proteins and electrophoresis fractions reported as absolute values in Groups 2 and 3.













𝑇0 7.2 6.6–7.8 6.5 6.3–6.8 6.7 6.5–7.2
𝑇21 7.1 6.8–7.6 6.8 6.0–7.7 7.0 6.7–7.5
𝑇42 7.1 6.6–7.6 6.5 6.2–7.4 6.8 6.5–7.3
𝑇100 NT NT 6.8 6.5–7.5 NT NT
𝑇250 6.6 6.5–7.8 NT NT NT NT
𝑇405 7.2 6.6–7.5 NT NT NT NT
Albumin
(2.6–4.1 g/dL)
𝑇0 3.5 3.2–4.1 3.4 3.1–3.5 3.4 3.3–3.5
𝑇21 3.5 3.2–3.7 3.3 2.9–3.9 3.4 3.3–3.7
𝑇42 3.5 3.3–3.7 3.3 3.0–3.7 3.4 3.2–3.6
𝑇100 NT NT 3.3 3.1–3.7 NT NT
𝑇250 3.4 3.1–3.6 NT NT NT NT
𝑇405 3.3 3.1–3.5 NT NT NT NT
Globulins
(2.5–4.5 g/dL)
𝑇0 3.6 3.0–4.2 3.2 2.8–3.6 3.2 3.0–3.6
𝑇21 3.7 3.5–3.9 3.4 3.0–3.8 3.5 3.3–3.8
𝑇42 3.5 3.2–4.0 3.3 3.2–3.7 3.5 3.3–3.7
𝑇100 NT NT 3.6 3.2–4.0 NT NT
𝑇250 3.5 3.1–4.4 NT NT NT NT




𝑇0 0.3 0.32–0.3 0.2 0.2–0.3 0.3 0.2–0.3
𝑇21 0.3 0.2–0.3 0.2 0.2–0.23 0.2 0.2–0.3
𝑇42 0.3 0.2–0.3 0.2 0.2–0.3 0.2 0.2–0.3
𝑇100 NT NT 0.2 0.2–0.3 NT NT
𝑇250 0.2 0.2–0.3 NT NT NT NT




𝑇0 1.0 0.7–1.2 1.0 0.8–1.1 1.0 0.9–1.1
𝑇21 1.0 0.9–1.0 1.1 1.0–1.3 1.0 0.9–1.1
𝑇42 0.9 0.8–1.0 1.1 1.0–1.1 1.0 0.9–1.1
𝑇100 NT NT 1.0 0.9–1.3 NT NT
𝑇250 1.0 0.9–1.2 NT NT NT NT
𝑇405 1.1 1.0–1.2 NT NT NT NT
Beta-1-globulins
(0.3–1.0 g/dL)
𝑇0 0.6∗ 0.4–0.8 0.6 0.3–0.9 0.6∗ 0.5–0.8
𝑇21 0.5∗ 0.4–0.5 0.5 0.4–0.6 0.5∗ 0.4–0.5
𝑇42 0.5∗ 0.4–0.5 0.4 0.4–0.5 0.5∗ 0.4–0.5
𝑇100 NT NT 0.4 0.3–0.7 NT NT
𝑇250 0.9∗ 0.5–1.0 NT NT NT NT
𝑇405 0.9∗ 0.4–1.1 NT NT NT NT
Beta-2-globulins
(0.4–1.1 g/dL)
𝑇0 1.0 0.3–1.8 0.7∗ 0.7–0.9 0.7 0.7–1.0
𝑇21 1.1 1.0–1.2 1.0∗ 0.7–1.1 1.0 0.9–1.1
𝑇42 1.0 0.9–1.2 1.0∗ 0.9–1.1 1.0 1.0–1.1
𝑇100 NT NT 1.2∗ 0.8–1.4 NT NT
𝑇250 0.9 0.6–1.1 NT NT NT NT




𝑇0 0.9 0.6–1.1 0.6 0.4–0.7 0.7 0.5–0.7
𝑇21 0.9 0.8–0.9 0.7 0.5–0.9 0.8 0.7–0.9
𝑇42 0.9 0.6–1.0 0.6 0.5–0.7 0.7 0.6–0.9
𝑇100 NT NT 0.7 0.5–0.9 NT NT
𝑇250 0.7 0.5–1.0 NT NT NT NT
𝑇405 0.8 0.6–0.9 NT NT NT NT
§Values in brackets are reference ranges.
NT = not tested.
∗Kruskal-Wallis test was 𝑃 > 0.05 for all time comparison for each group except where the asterisk next to the median values is reported (𝑃 < 0.05).
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Table 2: Immunoglobulin concentration in Group 2 (10 dogs).
Analyte§ Time Median 95% CI median
IgA (0.1–1.8mg/dL) 𝑇0 11.3 0.1–18.3
𝑇250 8.8 1.3–18.0
IgM (61–99mg/dL) 𝑇0 184.5 113.8–211.6
𝑇250 180.5 119.0–212.9
IgG (323–659mg/dL) 𝑇0 411.5
∗ 317.3–466.7
𝑇250 444.5∗ 352.8–467.5
§Values in brackets are reference ranges.
∗ =Wilcoxon test 𝑃 < 0.05.
Table 3: Immunoglobulin concentration in Group 3 (7 dogs).
Analyte§ Time Median 95% CI median
IgA (0.1–1.8mg/dL) 𝑇0 8.1 3.1–14.1
𝑇100 10.8 3.7–14.5
IgM (61–99mg/dL) 𝑇0 110.0
∗ 91.5–136.6
𝑇100 140.0∗ 116.9–158.6
IgG (323–659mg/dL) 𝑇0 497.0
∗ 448.9–566.5
𝑇100 575.0∗ 504.0–704.1
§Values in brackets are reference ranges.
∗ =Wilcoxon test 𝑃 < 0.05.
Table 4: IFAT L. infantum for the three groups of dogs.
Time Group 1 (𝑛) Group 2 (𝑛) Group 3 (𝑛)
𝑇0 Negative (6) Negative (12) Negative (9)
𝑇21 Not tested
Negative (10)
1 : 80 (1)
1 : 320 (1)
Negative (2)
1 : 80 (2)
1 : 160 (5)
𝑇42 Not tested
Negative (9)
1 : 40 (1)
1 : 80 (1)
1 : 320 (1)
Negative (1)
1 : 40 (1)
1 : 80 (3)
1 : 160 (3)
1 : 320 (1)
𝑇100 Not tested Not tested
Negative (5)
1 : 40 (3)
1 : 80 (1)
𝑇250
Negative (5)
1 : 80 (1)
Negative (10)
1 : 40 (1)




1 : 40 (2)
Negative (10)
1 : 40 (2) Not tested
𝑇770
Negative (4)
1 : 40 (2) Not tested Not tested
Group 2 two dogs at 𝑇21 and three dogs at 𝑇100 (during
the initial immunisation) showed variable titres up to 1 : 320.
At the following monitoring, only one dog was continuously
positive for all the observations. In Group 3 most of the
dogs were showing positive titre for IFAT after the initial
immunisation (𝑇21) and this trend was observed for the
other two collection points as well. All Speed Leish K tests


















Figure 1: IFAT positivity (%), Group 1.


















Figure 2: IFAT positivity (%), Group 2.
4. Discussion
In the present study the serological status of dogs after
the administration of CaniLeish was monitored up to the
second annual booster. No publications have so-far assessed
long-term IFAT titres modifications in vaccinated dogs. The
positivity was generally low and the trend is various for all
dogs. The prevalence recorded was 20.8% in Group 1, 15.0%
in Group 2, and 52.8% in Group 3. Many previous studies
reported an increase of IFAT titres after vaccination. Sagols
et al. demonstrated the seroconversion of dogs vaccinated
from 2 weeks to 4 months after the third shot and the
gradual decrease of titres in the following monitoring [17].
Moreno et al. indicated the increase of IFAT titres in all 20
vaccinated dogs at weeks 8 and 12 (maximum titre 1 : 500)
after the first injection and one dog still had a titre of 1 : 200
at week 30 [6]. All dogs became negative at IFAT (titre
<1 : 200) at week 42. Furthermore, in another study Sagols
et al. tested 31 vaccinated dogs after 3-4 weeks from the first
annual booster evidencing the increase of IFAT titres [18].




















Figure 3: IFAT positivity (%), Group 3.
Recently, Sagols et al. investigated the follow-up of the
humoral immune response after the first annual booster
recording an evolution of IFAT titres similar to the transient
profile obtained after the primary vaccination [19]. However,
IFAT results should be interpreted with caution in vaccinated
dogs, because they are obtained from a nonspecific test that
detects all IgG antibodies against the whole parasite, both due
to the contact with the parasite and due to the development
of immunological response. According to previous studies by
Sagols et al. all Speed Leish K assays remained negative, so
the antibodies detected by IFAT techniquewere not identified
by this test (immunochromatographic anti-kinesin antibody
test) [17–19]. Therefore, Sagols et al. demonstrated that this
rapid test is reliable for detecting antibodies due to the contact
with the parasite. On the other hand, Solano-Gallego et al.
have indicated that the sensitivity of rapid serological tests
used for dog screening prior to vaccination with CaniLeish
is rather low [20]. Thus, it is likely that some dogs will be
already Leishmania-infected at the time of vaccination, and
this will be a complicating factor for assessing vaccine efficacy
in the field. Moreover, the EFSA AHAW panel shows that
antibodies elicited on vaccinated dogs cannot be discrimi-
nated with current serological methods [21]. Until the advent
of vaccination in Europe, standard guidelines suggested that
IFAT titres of at least 4 times the laboratory cut-off level
were indicative of the disease and that levels between the
threshold and 4 times the threshold raised a suspicion of the
disease [22]. Nowadays, the literature agrees that the most
useful diagnostic approaches for investigation of infection
in sick and clinically healthy infected dogs include both the
detection of specific serum anti-Leishmania antibodies by
quantitative serological techniques and the demonstration of
the parasite DNA in tissues by applying specific molecular
techniques [1, 4, 21, 22].
To the author’s knowledge, no previous data about the
follow-up and monitoring of dogs vaccinated through hema-
tobiochemical and SPE analysis were published. Our results
for SPE showed the increase of few globulins fractions (𝛽-
globulins) that could be attributed to the immune response
induced by the vaccine. Proteins that migrate in each fraction
should be investigated individually, but this was not the
goal of this study. Additionally, modifications observed in Ig
quantification could be attributed to the immune stimulation
induced by the vaccine. The significant increase of total IgG
anti-Leishmania antibodies after vaccination with CaniLeish
is also demonstrated in other studies [5, 7].
In our study the limits were the low number of dogs
included, their different vaccination stages, the lack of PCR
analysis of blood to rule out the possibility of transmission
of L. infantum through bloodstocks, and the lack of ELISA
testing for dosing the level of IgG1 and IgG2 to assess the type
of immune response.The study is still continuing and further
data will be published.
5. Conclusions
In conclusion, the adoption of the vaccine CaniLeish in a
group of blood donors, typically healthy dogs as they are
frequently monitored all year long, could be a safe practice.
After vaccination there are only minimal modifications in
total protein contents, some globulins fractions, IgM and IgG,
and mild increase of IFAT titres.
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